Brenntag and SEQENS partner for the commercialization of non-GMP pharmaceutical intermediates in Europe
SEQENS and Brenntag are proud to announce a new strategic partnership for the distribution of non-GMP intermediates in Europe.
SEQENS, a global leader in specialty chemicals and pharmaceutical solutions, is pleased to announce the signing of a strategic partnership with Brenntag to strengthen the distribution of non-GMP intermediates across the European market.
High-quality products are a cornerstone of the pharmaceutical industry. At every stage of chemical synthesis—whether introducing a functional group, performing a coupling reaction, or modifying a molecular structure—the need for perfectly aligned intermediates, both in terms of quality and documentation, remains absolutely critical.
This partnership will deliver improved availability of non-GMP pharmaceutical intermediates, expanded coverage in Europe through Brenntag’s logistics and commercial expertise, quality assurance aligned with SEQENS standards, ensuring traceability and performance.
This collaboration enables to provide European pharmaceutical players with a reliable and competitive solution for their non-GMP intermediate needs, while optimizing lead times and flexibility.
“This partnership is part of our strategy to stay close to our customers and reinforce our presence in the European market. It enables us to respond quickly to market demands while maintaining our high standards of quality and safety,” said Alexandra Ngawa Zenang, Business Line Manager Pharma at SEQENS.
Learn more
About Brenntag:
Brenntag is the global market leader in chemicals and ingredients distribution. The company holds a central role in connecting customers and suppliers of the chemical industry. Headquartered in Essen, Germany, Brenntag has more than 18,100 employees worldwide and operates a network of around 600 sites in more than 70 countries. In 2024, Brenntag generated sales of 16.2 billion EUR. The two global divisions, Brenntag Essentials and Brenntag Specialties, provide a diversified and broad portfolio of industrial and specialty chemicals and ingredients as well as tailor-made application, marketing and supply chain solutions, technical and formulation support, comprehensive regulatory know-how, and digital solutions for a wide range of industries. Brenntag pursues an ambitious sustainability agenda and is committed to sustainable solutions in its own sector and the industries served. Brenntag shares have been listed at the Frankfurt Stock Exchange since 2010, in the DAX since September 2021. In addition, the Brenntag SE shares are listed in the DAX 30 ESG and DAX ESG Target. For more information, visit www.brenntag.com.
About SEQENS:
SEQENS is a global partner in health, personal care and specialty ingredients. We empower innovation to bring the best solutions to our customers, with a constant concern for sustainability. Relying on the skills of 3300 employees, we leverage a worldwide manufacturing network of 15 manufacturing sites and 9 state-of-the-art R&D centers in 9 countries. As an end-to-end player across the value chain, SEQENS offers a broad range of active ingredients, pharmaceutical intermediates, personal care & specialty ingredients. We innovate, develop and industrialize the most demanding molecules, and implement the best available technologies. Learn more at seqens.com.
